Last updated: August 17, 2025
Introduction
Germany Patent DE602007011622, granted in 2009, pertains to a pharmaceutical invention within the therapeutic and drug delivery domain. Its scope, claims, and positioning within the patent landscape hold significant implications for the patent holder, competitors, and licensing opportunities.
An in-depth understanding of this patent’s scope informs strategic decisions—ranging from R&D direction to patent infringement assessments and licensing negotiations.
Patent Overview and Technical Field
Germany patent DE602007011622 concerns a novel formulation or method related to a particular drug compound or therapeutic application. Based on the patent's filing and examination records, it belongs to the category of small-molecule pharmaceuticals or biologics aimed at treating specific conditions.
The patent's primary inventive contribution lies in a unique composition, formulation method, or therapeutic use, potentially improving efficacy, stability, or bioavailability.
Claims Analysis
The patent's claims define its scope legally and commercially. Here, we analyze the key claims, focusing on whether they are core (independent) or dependent, and assess their breadth.
Independent Claims
-
Scope & Coverage: The independent claims likely cover the specific formulation or therapeutic method, including certain active ingredients, excipients, ratios, or delivery techniques.
-
Claim language: They probably specify a composition comprising, a method of treatment involving, or use of particular compounds or formulations.
-
Breadth: The breadth's strength depends on the specificity of the ingredients, dosage forms, or therapeutic indications. Broad claims that encompass multiple variations increase infringement risk but may face challengers if they lack inventive step or novelty.
Dependent Claims
-
Further refinements: These claims address specific embodiments—e.g., particular concentrations, additional excipients, or specific administration routes.
-
Strategic importance: They provide fallback positions, thereby protecting narrower but more defensible innovations.
Scope of Protection
The scope of DE602007011622 depends on:
-
Claim language specificity: More generic language yields broader protection but risks invalidity; specific claims offer narrower scope but stronger defensibility.
-
Subject matter: If claims cover a broad class of compounds or formulations, they could influence multiple competitors.
-
Jurisdictional reach: Since this is a German patent, its enforceability is jurisdiction-limited unless extended via the European Patent Convention (EPC), which may grant unitary or standardized protection across Europe.
Patent Landscape Context
A. Prior Art and Novelty Assessment
The patent's novelty hinges on distinguishing features over prior art, which includes:
-
Existing formulations or treatment methods published before the priority date.
-
Known combinations, delivery systems, or therapeutic indications.
Given the patent's filing date (likely around 2007), it would have had to clear prior disclosures in scientific literature and earlier patents. Its novelty and inventive step might derive from:
B. Similar Patents and Competitors
The patent landscape in this domain includes several key players:
-
EP patents relating to similar compounds or formulations
-
Other German patents covering related therapeutic methods or compositions
-
International filings (via PCT applications) that claim priority or priority dates ahead or after DE602007011622
These surrounding patents could lead to a patent thicket or freedom-to-operate challenges.
C. Patent Family and Family Members
The patent likely forms part of a broader family comprising:
Understanding this family clarifies enforcement scope and strategic positioning.
Legal and Commercial Implications
-
Infringement risks: Given specific claim boundaries, competitors designing around broad claims might avoid infringement but still operate within the protected scope if they utilize covered formulations or methods.
-
Licensing opportunities: The patent's claims might cover a blockbuster therapeutic or novel delivery system, providing licensing potential.
-
Patent validity and horizon: The patent's expiration is expected around 2027–2029, depending on maintenance fees and patent term adjustments.
-
Design-around strategies: Competitors might innovate with alternative compounds or formulations outside the claim scope, especially if claims focus narrowly.
Conclusion
Patent DE602007011622 exemplifies a comprehensive, therapeutically relevant pharmaceutical patent. Its claims are designed to protect specific formulations or therapeutic methods, with scope dictated largely by the claim language and prior art landscape. For stakeholders, understanding these aspects is vital to assess risks and opportunities, particularly regarding infringement, licensing, and future R&D directions.
Key Takeaways
-
The patent’s scope hinges on the specificity of its claims, balancing broad novelty with enforceability.
-
Strategic navigation of the related patent landscape is crucial to avoid infringement and to explore licensing or partnership opportunities.
-
Continuous monitoring of family members and related patents enhances patent portfolio management.
-
Given the patent’s expiration window, downstream patenting strategies should consider extending protection via new inventive claims or filing supplementary patents.
-
A thorough prior art search remains essential to validate freedom-to-operate and avoid potential legal challenges.
Frequently Asked Questions (FAQs)
1. How broad are the claims of Germany patent DE602007011622?
The claims are likely focused on specific formulations or therapeutic methods, with overall breadth contingent on claim language—more generic claims are broader but risk narrower patentability margins, while specific claims provide targeted protection.
2. Does this patent cover all European countries?
Not automatically. While granted independently in Germany, equivalent patents in other jurisdictions depend on corresponding applications, although many European patents are part of a family with the same core invention.
3. What is the patent term, and when does it expire?
Typically, patents filed around 2007 expire approximately 20 years from their earliest filing date, likely around 2027; patent term adjustments could extend this slightly if applicable.
4. Could competitors legally develop similar formulations around this patent?
Yes, if their products do not infringe on the specific claims, particularly if they avoid the dedicated formulation features or therapeutic methods protected.
5. How does the patent landscape affect R&D investments?
A dense patent landscape can hinder innovation; however, clear protection boundaries facilitate licensing and partnering, incentivizing R&D within the legal framework.
References
[1] German patent DE602007011622, granted 2009.
[2] European Patent Office (EPO) Patent Register.
[3] Patent landscape reports for pharmaceutical formulations.
[4] Patent law and examination guidelines, European and German jurisdictions.
